Design of recombinant bacteriocin fusion protein and evaluation of its anticancer and antibacterial activity
Microbial Pathogenesis · 2025
DOI: 10.1016/j.micpath.2025.107633 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Pathogenesis, 2025. Verfasst von Narges Yadollahi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Shahr-e-Quds Branch, Islamic Azad University, Tehran, Iran. Hauptthemen laut MEDLINE: Bacteriocins, Anti-Bacterial Agents, Antineoplastic Agents, Recombinant Fusion Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Baqiyatallah University of Medical Sciences.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVES: Gastrointestinal cancer is the fifth most common cause of cancer in the world, and its treatment is currently challenging. Bacteriocins are cationic proteins that are produced by the ribosome. Many bacteriocins exhibit cytotoxicity against cancer cells and are attractive candidates for future research. In this study, the anticancer and antibacterial activity of a recombinant six bacteriocin fusion protein bifidocin, enterocin, nisin, thermophilin, epidermycin, and colicin (BENTEC) was investigated against the AGS cancer cell line and important gram-positive and gram-negative pathogens. METHODS: The NCBI database provided the gene sequences. The specific ligand of the AGS cell line and the anticancer sequences were added to the recombinant construct. The physical-chemical characteristics of recombinant bacteriocin were assessed by bioinformatics methods. Expression of the recombinant vector pET22b was performed in E. coli BL21(DE3). MTT test was used to evaluate the cytotoxicity in AGS cell lines and normal GES-1 cells. Flow cytometry and Real-Time PCR methods were used to investigate the expression changes of apoptotic genes against the AGS cell line. The anti-bacterial activity of BENTC fusion bacteriocin against Escherichia coli and Enterococcus faecalis was evaluated by MIC, MBC, and disc diffusion methods. RESULTS: The recombinant BENTEC fusion bacteriocin contains 424 amino acids, a molecular weight of 47KD, and an isoelectric point of 11.17. The GRAVY score is -0.596, indicating the hydrophilic properties of the fusion bacteriocin. MTT results demonstrated that 52 % of AGS cell lines treated with a concentration of 8 μg/mL of BENTEC fusion bacteriocin were destroyed during 24 hours. Flow cytometry showed that recombinant bacteriocin induced 76.4 % of apoptosis in the treated cell lines (63.7 % early apoptosis and 12.7 % late apoptosis). Real-time RT- PCR indicated that recombinant BENTEC increased expression of the Bax and Caspase 3 genes by 4.53 fold and 5.856 fold, respectively, and decreased gene expression of bcl-2 by 0.18 fold in the AGS line cell. The results demonstrated that the MIC and MBC for E. coli and E. faecalis were 5 μg/ml,10 μg/ml,10 μg/ml, and 20 μg/ml, respectively. Disc diffusion showed that the diameters of the growth inhibition zones for E. coli and E. faecalis were 32 mm and 23 mm, respectively. CONCLUSION: The results of this study showed that the fusion protein of six bacteriocins linked to the anticancer and the specific ligand sequences was able to induce apoptosis in AGS cell line and have antibacterial activity against important gram-positive and gram-negative pathogens at lower concentrations and with greater specificity. Collectively, BENTEC fusion bacteriocin may be regarded as a promising option for anticancer and antibacterial therapy or prophylaxis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Shahr-e-Quds Branch, Islamic Azad University, Tehran, Iran.
- Department of Microbiology and Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: esm114@gmail.com.
Förderung
- Baqiyatallah University of Medical Sciences
Zitieren
APA
Yadollahi, N., Mohamadian, T., Esmaeili, D., & Forohi, F. (2025). Design of recombinant bacteriocin fusion protein and evaluation of its anticancer and antibacterial activity. Microbial Pathogenesis. https://doi.org/10.1016/j.micpath.2025.107633
Vancouver
Yadollahi N, Mohamadian T, Esmaeili D, Forohi F. Design of recombinant bacteriocin fusion protein and evaluation of its anticancer and antibacterial activity. Microbial Pathogenesis. 2025. doi:10.1016/j.micpath.2025.107633
BibTeX
@article{Yadollahi2025,
author = {Yadollahi, Narges and Mohamadian, Taher and Esmaeili, Davoud and Forohi, Fatemeh},
title = {Design of recombinant bacteriocin fusion protein and evaluation of its anticancer and antibacterial activity},
journal = {Microbial Pathogenesis},
year = {2025},
doi = {10.1016/j.micpath.2025.107633}
}
EUVIMED